Please assess the completion status of the following clinical trial:

Trial Title: Chronic Hypertension and Pregnancy (CHAP) Project

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with chronic hypertension in pregnancy with new or untreated chronic hypertension, blood pressure 140-159 systolic or 90-104 diastolic OR known chronic hypertension on monotherapy and taking any antihypertensive and blood pressure ≤159/104 (including those with blood pressure \<140/90);~2. Singleton; and~3. viable pregnancy \<23 weeks of gestation.~Exclusion Criteria:~1. Blood pressures prior to randomization ≥160 systolic or ≥105 diastolic (with or without treatment);~2. Severe hypertension including patients currently treated with \>1 antihypertensive medication (more likely to have severe chronic hypertension);~3. Multi-fetal pregnancy;~4. Known secondary cause of chronic hypertension;~5. High-risk co-morbidities for which treatment may be indicated:~   * Diabetes mellitus diagnosed at age ≤10 years or duration of diagnosis ≥20 years~  * Diabetes mellitus complicated by end organ damage (retinopathy, nephropathy, heart disease, transplant)~  * Chronic kidney disease - including baseline proteinuria (\>300mg/24-hr, protein/creatinine ratio ≥0.3, or persistent 1+ proteinuria\*) or creatinine \>1.2.~     \*If a dipstick value at screening is more than trace, a clean catch or catheter urine should be obtained and re-tested by dipstick. If this shows trace or absence of protein, the patient is included. If it again shows 1+ protein, the patient is excluded until a 24-hr urine \<300mg/24hr or p/c ratio is \<0.3. If a p/c ratio is \>0.3, the patient may be included if a 24-hour urine is \< 300 mg.~  * Cardiac disorders: cardiomyopathy, angina, CAD~  * Prior stroke~  * Retinopathy~  * Sickle cell disease~6. Known major fetal anomaly;~7. Known fetal demise;~8. Suspected IUGR;~9. Membrane rupture or planned termination prior to randomization;~10. Plan to deliver outside the consortium centers (unless approved by the Clinical Coordinating Center) or unlikely to follow-up in the opinion of study staff or previous participation in this trial;~11. Contraindication to labetalol and nifedipine (e.g. know hypersensitivity);~12. Current substance abuse or addiction (cocaine, methamphetamine)~13. Participation in another trial without prior approval (CHAP participants will not be enrolled in other trials without prior approval by protocol committee)~14. Physician or provider refusal~15. Patient refusal \*The minimum age varies by center

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-hypertensive therapy to goal <140/90 mmHg (Type: EXPERIMENTAL): Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
- No anti-hypertensive unless BP is severe (≥160/105 mmHg (Type: ACTIVE_COMPARATOR): Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used

Based on this trial design, predict the completion outcome and termination type (if applicable).